The Food and Drug Administration (FDA) has posted a discontinuation notice for Fortical (calcitonin-salmon [rDNA origin]; Upsher-Smith) Nasal Spray effective September 30, 2016.

Fortical Nasal Spray, a hormone therapy, is indicated for the treatment of postmenopausal osteoporosis. It is supplied as a 2200 IU/mL strength in 3.7mL bottles with NDC 0245-0008-35. 

Related Articles

Calcitonin-salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. It appears to have actions essentially identical to calcitonins of mammalian origin but its potency per milligram is greater with a longer duration of action. Its exact mechanisms in normal human bone physiology are still not completely elucidated.

For more information call (800) 654-2299 or visit